Skip to main content Accessibility help
×
Home

Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials

  • Katherine H. O. Deane (a1), Oluseyi F. Jimoh (a2), Priti Biswas (a3), Alex O'Brien (a4), Sarah Hanson (a5), Asmaa S. Abdelhamid (a6), Chris Fox (a7) and Lee Hooper (a8)...

Abstract

Background

There is strong public belief that polyunsaturated fats protect against and ameliorate depression and anxiety.

Aims

To assess effects of increasing omega-3, omega-6 or total polyunsaturated fat on prevention and treatment of depression and anxiety symptoms.

Method

We searched widely (Central, Medline and EMBASE to April 2017, trial registers to September 2016, ongoing trials updated to August 2019), including trials of adults with or without depression or anxiety, randomised to increased omega-3, omega-6 or total polyunsaturated fat for ≥24 weeks, excluding multifactorial interventions. Inclusion, data extraction and risk of bias were assessed independently in duplicate, and authors contacted for further data. We used random-effects meta-analysis, sensitivity analyses, subgrouping and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) assessment.

Results

We included 31 trials assessing effects of long-chain omega-3 (n = 41 470), one of alpha-linolenic acid (n = 4837), one of total polyunsaturated fat (n = 4997) and none of omega-6. Meta-analysis suggested that increasing long-chain omega-3 probably has little or no effect on risk of depression symptoms (risk ratio 1.01, 95% CI 0.92–1.10, I2 = 0%, median dose 0.95 g/d, duration 12 months) or anxiety symptoms (standardised mean difference 0.15, 95% CI 0.05–0.26, I2 = 0%, median dose 1.1 g/d, duration 6 months; both moderate-quality evidence). Evidence of effects on depression severity and remission in existing depression were unclear (very-low-quality evidence). Results did not differ by risk of bias, omega-3 dose, duration or nutrients replaced. Increasing alpha-linolenic acid by 2 g/d may increase risk of depression symptoms very slightly over 40 months (number needed to harm, 1000).

Conclusions

Long-chain omega-3 supplementation probably has little or no effect in preventing depression or anxiety symptoms.

Declaration of interest

L.H. and A.A. were funded to attend the World Health Organization Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health meetings and present review results. The authors report no other conflicts of interest.

Copyright

Corresponding author

Correspondence: Lee Hooper, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. Email: l.hooper@uea.ac.uk

References

Hide All
1Papanikolaou, Y, Brooks, J, Reider, C, Fulgoni, VL. U.S. adults are not meeting recommended levels for fish and omega-3 fatty acid intake: results of an analysis using observational data from NHANES 2003–2008. Nutr J 2014; 13: 31.
2Kyu, HH, Abate, D, Abate, KH, Abay, SM, Abbafati, C, Abbasi, N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1859–922.
3Demyttenaere, K, Bruffaerts, R, Posada-Villa, J, Gasquet, I, Kovess, V, Lepine, JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291(21): 2581–90.
4Kessler, RC, Angermeyer, M, Anthony, JC, De Graaf, R, Demyttenaere, K, Gasquet, I, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. World Psychiatry 2007; 6(3): 168–76.
5Wang, J, Wu, X, Lai, W, Long, E, Zhang, X, Li, W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open 2017; 7(8): e017173.
6Broen, MPG, Narayen, NE, Kuijf, ML, Dissanayaka, NNW, Leentjens, AFG. Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2016; 31(8): 1125–33.
7Matcham, F, Rayner, L, Steer, S, Hotopf, M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2136–48.
8Dyall, SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci 2015; 7: 52.
9Su, K-P, Matsuoka, Y, Pae, C-U. Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. Clin Psychopharmacol Neurosci 2015; 13(2): 129–37.
10Larrieu, T, Layé, S. Food for mood: relevance of nutritional omega-3 fatty acids for depression and anxiety. Front Physiol 2018; 9: 1047.
11Grosso, G, Micek, A, Marventano, S, Castellano, S, Mistretta, A, Pajak, A, et al. Dietary n-3 PUFA, fish consumption and depression: a systematic review and meta-analysis of observational studies. J Affect Disord 2016; 205: 269–81.
12Thesing, CS, Bot, M, Milaneschi, Y, Giltay, EJ, Penninx, BWJH. Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders. Psychoneuroendocrinology 2018; 87: 5362.
13Green, P, Hermesh, H, Monselise, A, Marom, S, Presburger, G, Weizman, A. Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 2006; 16(2): 107–13.
14Appleton, KM, Sallis, HM, Perry, R, Ness, AR, Churchill, R. Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev 2015; 11: CD004692.
15Abdelhamid, AS, Brown, TJ, Brainard, JS, Biswas, P, Thorpe, GC, Moore, HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 11: CD003177.
16Abdelhamid, AS, Martin, N, Bridges, C, Brainard, JS, Wang, X, Brown, TJ, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 11: CD012345.
17Hooper, L, Al-Khudairy, L, Abdelhamid, AS, Rees, K, Brainard, JS, Brown, TJ, et al. Omega-6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 11: CD011094.
18Abdelhamid, A, Hooper, L, Sivakaran, R, Hayhoe, RPG, Welch, A, The PUFAH Group. The relationship between omega-3, omega-6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta-analysis of RCTs. Calcif Tissue Int 2019; 105: 353–72.
19Brown, TJ, Brainard, J, Song, F, Wang, X, Abdelhamid, A, Hooper, L. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ 2019; 366: l4697.
20Brainard, J, Jimoh, OF, Deane, K, Biswas, P, Donaldson, D, Maas, K, et al. Omega-3, omega-6 and total polyunsaturated fat for cognition and dementia: systematic review and meta-analysis of RCTs. JAMDA, in press, 2019.
21Hanson, S, Thorpe, G, Winstanley, L, Abdelhamid, AS, Hooper, L. Omega-3, omega-6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta-analysis of randomised trials. Br J Cancer, in press, 2019.
22Hooper, L, Abdelhamid, A, Brainard, J, Deane, KHO, Song, F. Creation of a database to assess effects of omega-3, omega-6 and total polyunsaturated fats on health: database and methodology for a set of reviews. BMJ Open 2019; 9(5): e029554.
23Thorpe, G, Ajabnoor, S, Ahmed, Z, Abdelhamid, A, Hooper, L. Dietary Polyunsaturated Fat for Prevention and Treatment of Inflammatory Bowel Disease. PROSPERO, 2017 (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=68704).
24Browning, LM, Walker, CG, Mander, AP, West, AL, Madden, J, Gambell, JM, et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012; 96(4): 748–58.
25Higgins, JPT, Altman, DG, Sterne, JAC, Cochrane Statistical Methods Group, Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 510 [updated March 2011] (eds Higgins, JPT, Green, S): section 8.5. The Cochrane Collaboration, 2011.
26McKenzie, JE, Herbison, GP, Deeks, JJ. Impact of analysing continuous outcomes using final values, change scores and analysis of covariance on the performance of meta-analytic methods: a simulation study. Res Synth Methods 2016; 7(4): 371–86.
27Review Manager (RevMan) Version 5.3. The Cochrane Collaboration, 2014 (https://community.cochrane.org/help/tools-and-software/revman-5/revman-5-download/installation).
28Tajalizadekhoob, Y, Sharifi, F, Fakhrzadeh, H, Mirarefin, M, Ghaderpanahi, M, Badamchizade, Z, et al. The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci 2011; 261(8): 539–49.
29Harbord, RM, Egger, M, Sterne, JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 2006; 25(20): 3443–57.
30Kromhout, D, Giltay, EJ, Geleijnse, JM. Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363(21): 2015–26.
31Chew, EY, Clemons, TE, Agron, E, Launer, LJ, Grodstein, F, Bernstein, PS, et al. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA 2015; 314(8): 791801.
32Chiu, CC, Su, KP, Cheng, TC, Liu, HC, Chang, CJ, Dewey, ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1538–44.
33Burr, ML, Ashfield-Watt, PA, Dunstan, FD, Fehily, AM, Breay, P, Ashton, T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57(2): 193200.
34Derosa, G, Cicero, AF, D'Angelo, A, Borghi, C, Maffioli, P. Effects of n-3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors 2016; 42(3): 316–22.
35Tokudome, S, Kuriki, K, Yokoyama, Y, Sasaki, M, Joh, T, Kamiya, T, et al. Dietary n-3/long-chain n-3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. Prostaglandins Leukot Essent Fatty Acids 2015; 94: 111.
36Einvik, G, Ekeberg, O, Lavik, JG, Ellingsen, I, Klemsdal, TO, Hjerkinn, EM. The influence of long-term awareness of hyperlipidemia and of 3 years of dietary counseling on depression, anxiety, and quality of life. J Psychosom Res 2010; 68(6): 567–72.
37Sanyal, AJ, Abdelmalek, MF, Suzuki, A, Cummings, OW, Chojkier, M, Group, E. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014; 147(2): 377–84.
38Danthiir, V, Hosking, D, Burns, NR, Wilson, C, Nettelbeck, T, Calvaresi, E, et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n-3 fatty acids. J Nutr 2014; 144(3): 311–20.
39Ferreira, JJ, Rosser, A, Craufurd, D, Squitieri, F, Mallard, N, Landwehrmeyer, B. Ethyl-eicosapentaenoic acid treatment in Huntington's disease: a placebo-controlled clinical trial. Mov Disord 2015; 30(10): 1426–9.
40Hashimoto, M, Kato, S, Tanabe, Y, Katakura, M, Mamun, AA, Ohno, M, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. Geriatr Gerontol Int 2016; 17(2): 330–7.
41Jackson, PA, Forster, JS, Bell, JG, Dick, JR, Younger, I, Kennedy, DO. DHA supplementation alone or in combination with other nutrients does not modulate cerebral hemodynamics or cognitive function in healthy older adults. Nutrients 2016; 8: 86.
42Lee, SP, Dart, AM, Walker, KZ, O'Dea, K, Chin-Dusting, JP, Skilton, MR. Effect of altering dietary n-6:n-3 PUFA ratio on cardiovascular risk measures in patients treated with statins: a pilot study. Br J Nutr 2012; 108(7): 1280–5.
43Vellas, B, Carrie, I, Guyonnet, S, Touchon, J, Dantoine, T, Dartigues, JF, et al. MAPT (multi-domain Alzheimer's prevention trial): results at 36 months. Alzheimer's Dement 2015; 11: 331.
44Van De Rest, O, Geleijnse, JM, Kok, FJ, van Staveren, WA, Dullemeijer, C, Olderikkert, MG, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008; 71(6): 430–8.
45Yurko-Mauro, K, McCarthy, D, Rom, D, Nelson, EB, Ryan, AS, Blackwell, A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's Dement 2010; 6(6): 456–64.
46McGorry, PD, Nelson, B, Markulev, C, Yuen, HP, Schäfer, MR, Mossaheb, N, et al. Effect of ω−3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry 2017; 74(1): 1927.
47Torkildsen, O, Wergeland, S, Bakke, S, Beiske, AG, Bjerve, KS, Hovdal, H, et al. Omega-3 fatty acid treatment in multiple sclerosis (OFAMS study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012; 69(8): 1044–51.
48Pawelczyk, T, Grancow-Grabka, M, Kotlicka-Antczak, M, Trafalska, E, Pawelczyk, A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res 2016; 73: 3444.
49Freund-Levi, Y, Basun, H, Cederholm, T, Faxen-Irving, G, Garlind, A, Grut, M, et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23(2): 161–9.
50Rauch, B, Schiele, R, Schneider, S, Diller, F, Victor, N, Gohlke, H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010; 122(21): 2152–9.
51Dangour, AD, Allen, E, Elbourne, D, Fasey, N, Fletcher, AE, Hardy, P, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010; 91(6): 1725–32.
52Palma, C. Omega 3 fatty acids supplementation in Schizophrenia. Eur Arch Psychiatry Clin Neurosci 2015; 265(Suppl 1): S122-S.
53Pomponi, M, Loria, G, Salvati, S, Di Biase, A, Conte, G, Villella, C, et al. DHA effects in Parkinson disease depression. Basal Ganglia 2014; 4(2): 61–6.
54Pratt, CM, Reiffel, JA, Ellenbogen, KA, Naccarelli, GV, Kowey, PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J 2009; 158(2): 163–9.
55Sinn, N, Milte, CM, Street, SJ, Buckley, JD, Coates, AM, Petkov, J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012; 107(11): 1682–93.
56Galan, P, Kesse-Guyot, E, Czernichow, S, Briancon, S, Blacher, J, Hercberg, S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010; 341: c6273.
57Tuttle, KR, Shuler, LA, Packard, DP, Milton, JE, Daratha, KB, Bibus, DM, et al. Comparison of low-fat versus Mediterranean-style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). Am J Cardiol 2008; 101(11): 1523–30.
58Huntington Study Group. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65(12): 1582–9.
59ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018; 379(16): 1540–50.
60Andrieu, S, Guyonnet, S, Coley, N, Cantet, C, Bonnefoy, M, Bordes, S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol 2017; 16(5): 377–89.
61Van De Rest, O, Geleijnse, JM, Kok, FJ, van Staveren, WA, Hoefnagels, WH, Beekman, AT, et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88(3): 706–13.
62Estruch, R, Ros, E, Salas-Salvadó, J, Covas, M, Corella, D, Arós, F, et al. Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013;368:1279-90. N Engl J Med 2018; 378: 2441–2.
63Bot, M, Brouwer, IA, Roca, M, Kohls, E, Penninx, BWJH, Watkins, E, et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms: the MooDFOOD randomized clinical trial. JAMA 2019; 321(9): 858–68.
64Su, K-P, Tseng, P-T, Lin, P-Y, Okubo, R, Chen, T-Y, Chen, Y-W, et al. Association of use of omega-3 polyunsaturated fatty acids with changes in severity of anxiety symptoms: a systematic review and meta-analysis. JAMA Netw Open 2018; 1(5): e182327.
65Mocking, RJ, Harmsen, I, Assies, J, Koeter, MW, Ruhe, HG, Schene, AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder. Transl Psychiatry 2016; 6: e756.
66Bai, Z-G, Bo, A, Wu, S-J, Gai, Q-Y, Chi, I. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: a systematic review and meta-analysis. J Affect Disord 2018; 241: 241–8.
67Hallahan, B, Ryan, T, Hibbeln, JR, Murray, IT, Glynn, S, Ramsden, CE, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry 2018; 209(3): 192201.
68Yang, JR, Han, D, Qiao, ZX, Tian, X, Qi, D, Qiu, XH. Combined application of eicosapentaenoic acid and docosahexaenoic acid on depression in women: a meta-analysis of double-blind randomized controlled trials. Neuropsychiatr 2015; 11: 2055–61.
69Geleijnse, J, Giltay, E, Kromhout, D. Effects of n-3 fatty acids on cognitive decline: a randomized double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimer's Dement 2011; 1: S512.
70Burr, ML, Ashfield-Watt, PA, Dunstan, FD, Fehily, AM, Breay, P, Ashton, T, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57(2): 193200.

Keywords

Type Description Title
WORD
Supplementary materials

Deane et al. supplementary material
Deane et al. supplementary material

 Word (764 KB)
764 KB

Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials

  • Katherine H. O. Deane (a1), Oluseyi F. Jimoh (a2), Priti Biswas (a3), Alex O'Brien (a4), Sarah Hanson (a5), Asmaa S. Abdelhamid (a6), Chris Fox (a7) and Lee Hooper (a8)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Omega-3 and polyunsaturated fat for prevention of depression and anxiety symptoms: systematic review and meta-analysis of randomised trials

  • Katherine H. O. Deane (a1), Oluseyi F. Jimoh (a2), Priti Biswas (a3), Alex O'Brien (a4), Sarah Hanson (a5), Asmaa S. Abdelhamid (a6), Chris Fox (a7) and Lee Hooper (a8)...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *